The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney

Int J Mol Sci. 2022 Oct 9;23(19):11987. doi: 10.3390/ijms231911987.

Abstract

In the essential homeostatic role of kidney, two intrarenal mechanisms are prominent: the glomerulotubular balance driving the process of Na+ and water reabsorption in the proximal tubule, and the tubuloglomerular feedback which senses the Na+ concentration in the filtrate by the juxtaglomerular apparatus to provide negative feedback on the glomerular filtration rate. In essence, the two mechanisms regulate renal oxygen consumption. The renal hyperfiltration driven by increased glomerular filtration pressure and by glucose diuresis can affect renal O2 consumption that unleashes detrimental sympathetic activation. The sodium-glucose co-transporters inhibitors (SGLTi) can rebalance the reabsorption of Na+ coupled with glucose and can restore renal O2 demand, diminishing neuroendocrine activation. Large randomized controlled studies performed in diabetic subjects, in heart failure, and in populations with chronic kidney disease with and without diabetes, concordantly address effective action on heart failure exacerbations and renal adverse outcomes.

Keywords: GFR; SGLT2; diabetes; glomerular filtration rate; glomerular hyperfiltration; heart failure; inhibitors; renal failure; sodium-glucose co-transporter-2.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus*
  • Diabetic Nephropathies*
  • Glomerular Filtration Rate / physiology
  • Heart Failure* / drug therapy
  • Humans
  • Kidney / metabolism
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors

Grants and funding

This research received no external funding.